Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557066 | 1.00 | HTR2A (0.56) | HTR2AHTR2CHTR2BACHEDRD2 | |
| Trifluoroacetic Acid SCHEMBL3550913 | 0.92 | HTR2A (0.49) | HTR2AHTR2CHTR2BACHEDRD2 | |
| SCHEMBL3560321 | 0.85 | HTR2A (0.54) | HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL3560318 | 0.85 | HTR2A (0.54) | HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL3553758 | 0.84 | HTR2A (0.55) | HTR2AHTR2CHTR2BDRD2HTR1A | |
| SCHEMBL3553756 | 0.84 | HTR2A (0.55) | HTR2AHTR2CHTR2BDRD2HTR1A | |
| SCHEMBL3565220 | 0.83 | DRD2 (0.50) | HTR2AHTR2CHTR2BDRD2HTR1A | |
| SCHEMBL3565223 | 0.83 | DRD2 (0.50) | HTR2AHTR2CHTR2BDRD2HTR1A | |
| SCHEMBL3557100 | 0.81 | DRD2 (0.48) | HTR2AHTR2CHTR2BDRD2HTR1A | |
| SCHEMBL3557457 | 0.81 | CHRM4 (0.43) | HTR2AHTR2CHTR2BACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7812024-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR5A, HTR1A, HTR2A | HTR2A 3/4885HTR2C 5/4885HTR2B 4/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | HTR2A 4/4885HTR2C 6/4885HTR2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.